Figure 7.

B cell-depleting IS therapy mitigates AAV8 uptake

Control mice (no-IS) or mice pretreated with α-CD20+Ext α-BAFF initially received 1 × 10¹¹ vg/mouse AAV8-OVA, followed by re-administration with AAV8-Atto-590 12 weeks later. Naive mice received AAV8-Atto-590 only (n = 4–6/group). (A) Proportion of neutrophils, monocytes, MZMs, metallophilic macrophages (MMM) and DCs from splenocytes that take up AAV8-Atto-590. (B) Proportion of neutrophils, monocytes, Kupffer cells, and DCs from the liver that take up AAV8-Atto-59. Statistical significance was calculated by 1-way ANOVA (Dunnett’s multiple comparisons). ∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001; ∗∗∗∗p ≤ 0.0001.